

# Boletín bibliográfico

## Enfermedad de Machado-Joseph

La ataxia es una enfermedad rara de origen genético que se caracteriza por alteraciones neuromusculares debidas a la pérdida selectiva de neuronas en el cerebelo, el órgano de nuestro sistema nervioso encargado de controlar el movimiento y el equilibrio.

Investigadores de la Universidad de Barcelona (UB) han identificado nuevas funciones del gen ataxina 3 (ATXN3) --causante de la enfermedad de Machado-


Joseph, el tipo de ataxia más frecuente-- en el desarrollo de los fotorreceptores de la retina.

Según los investigadores, estos resultados son relevantes no solo para profundizar en las causas moleculares de la ataxia y en el diseño de potenciales terapias contra ella, sino también para comprender otras enfermedades, como las degeneraciones maculares.

La enfermedad de Machado-Joseph, también llamada ataxia espinocerebelosa de tipo 3, está causada por mutaciones dominantes de ganancia de función del gen ATXN3.

Dichas mutaciones inducen la formación de agregados neurotóxicos que conllevan la muerte progresiva de las neuronas cerebelares. No obstante, se sabe muy poco de cuál es la función básica del gen ATXN3.

**Amazings**



## SCA 3



- SCA3 o Enfermedad de Machado Joseph (EMJ) es la SCA mas frecuente en la mayoría de poblaciones.
- Se ha descrito como ataxia cerebelosa pura, parkinsonismo familiar, paraplegia espástica hereditaria, neuropatía hereditaria y síndrome de piernas inquietas.
- Tiene una frecuencia relativa del 1-63% y se debe a la mutación en el locus 14q32.1, con una expansión de 51-89 tripletes CAG

## TRANSMISIÓN DOMINANTES (teorías)




Un solo gen defectuoso  
basta para ser afectado

**NORMAL**

**AFECTADA**

gen normal   gen normal

gen normal   gen alterado



**NORMAL   NORMAL   AFECTADA   AFECTADO**



$$25 \% + 25 = 50 \%$$

$$25 \% + 25 \% = 50 \%$$

La incidencia por sexos, el orden, y los porcentajes reales,  
quedan sujetos al azar y sin posibilidad de ser definidos

## Referencias bibliográficas

- A**kçimen F, Martins S, Liao C, Bourassa CV, Catoire H, Nicholson GA, et al. Genome-wide association study identifies genetic factors that modify age at onset in Machado-Joseph disease. *Aging (Albany NY)* [Internet]. 2020 [citado 11 dic 2020]; 12(6). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138549/pdf/aging-12-102825.pdf>.
- A**ldawoodi NN, Escher AR, Jr. Sentinel Node Biopsy and Lumpectomy in a Patient with Machado-Joseph Disease. *Case Rep Anesthesiol* [Internet]. 2019 [citado 11 dic 2020]; 2019. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942782/pdf/CRIA2019-2309598.pdf>.
- A**njanappa RM, Jain S, Wali GM, Purushottam M. Genetic analysis of a family from India with Machado-Joseph disease. *Neurology India* [Internet]. 2019 [citado 11 dic 2020]; 67(2). Disponible en: <https://www.neurologyindia.com/article.asp?issn=0028-3886;year=2019;volume=67;issue=2;spage=582;epage=588;aulast=Anjanappa;type=2>.
- A**shraf NS, Sutton JR, Yang Y, Ranxhi B, Li-bohova K, Shaw ED, et al. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein. *Neurobiology of Disease* [Internet]. 2020 [citado 11 dic 2020]; 137. Disponible en: <https://www.sciencedirect.com/science/article/pii/S0969996119303729/pdf?md5=896f7728c000b82661e0d78852927cfe&pid=1-s2.0-S0969996119303729-main.pdf>.
- B**uijsen RAM, Toonen LJA, Gardiner SL, van Roon-Mom WMC. Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias. *Neurotherapeutics* [Internet]. 2019 [citado 11 dic 2020]; 16(2). Disponible en: <https://link.springer.com/content/pdf/10.1007/s13311-018-00696-y.pdf>.
- C**atai LMP, Camargo CHF, Moro A, Ribas G, Raskin S, Teive HAG. Dystonia in Patients with Spinocerebellar Ataxia 3 - Machado-Joseph disease: An Underestimated Diagnosis? *The open neurology journal* [Internet]. 2018 [citado 11 dic 2020]; 12. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008980/pdf/TONEUJ-12-41.pdf>.
- C**hen YS, Hong ZX, Lin SZ, Harn HJ. Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies. *Int J Mol Sci* [Internet]. 2020 [citado 11 dic 2020]; 21(9). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246822/pdf/ijms-21-03063.pdf>.
- C**iolak A, Krzyzosiak WJ, Kozłowska E, Fiszer A. Generation of human iPS cell line IBCHi002-A from spinocerebellar ataxia type 3/Machado-Joseph disease patient's fibroblasts. *Stem Cell Research* [Internet]. 2020 [citado 11 dic 2020]; 45. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1873506120300994/pdf?md5=89d2d41a1c94a21d4b7d86c4c13d71b4&pid=1-s2.0-S1873506120300994-main.pdf>.

---

**C**osta MDC, Radzwion M, McLoughlin HS, Ashraf NS, Fischer S, Shakkottai VG, et al. In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3. *Movement disorders : official journal of the Movement Disorder Society* [Internet]. 2020 [citado 11 dic 2020]; 35(10). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572607/pdf/nihms-1610956.pdf>.

**D**ongxue Ding, Chunrong Wang, Zhao Chen, Huirong Peng, Kai Li, Xin Zhou, et al. Polymorphisms in DNA methylation-related genes are linked to the phenotype of Machado-Joseph disease. *Neurobiology of Aging* [Internet]. 2019 [citado 11 dic 2020]; 75. Disponible en: [https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0197458018304032.pdf?locale=es\\_ES&searchIndex=](https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0197458018304032.pdf?locale=es_ES&searchIndex=).

**D**uarte Lobo D, Nobre RJ, Oliveira Miranda C, Pereira D, Castelhana J, Sereno J, et al. The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples. *Acta Neuropathologica Communications* [Internet]. 2020 [citado 11 dic 2020]; 8(1). Disponible en: <https://actaneurocomms.biomedcentral.com/track/pdf/10.1186/s40478-020-00955-0.pdf>.

**F**arias AM, Appenzeller S, França MC, Martinez AR, Etchebehere EE, Souza TF, et al. Assessment of Bone Mineral Density of Patients with Spinocerebellar Ataxia Type 3. *Journal of movement disorders* [Internet]. 2019 Jan [citado 11 dic 2020];

12(1). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369376/pdf/jmd-18041.pdf>.

**F**urtado GV, Oliveira CM, Bolzan G. State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change. *Genetics and molecular biology* [Internet]. 2019 [citado 11 dic 2020]; 42(1 suppl 1). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687346/pdf/1415-4757-GMB-1678-4685-GMB-2018-0103.pdf>.

**H**ernandez-Castillo CR, Diaz R, Campos-Romo A, Fernandez-Ruiz J. Neural correlates of ataxia severity in spinocerebellar ataxia type 3/Machado-Joseph disease. *Cerebellum & Ataxias* [Internet]. 2017 [citado 11 dic 2020]; 4(1). Disponible en: <https://cerebellumandataxias.biomedcentral.com/track/pdf/10.1186/s40673-017-0065-7.pdf>.

**H**erzog LK, Kevei É, Marchante R, Böttcher C, Bindesbøll C, Lystad AH, et al. The Machado-Joseph disease deubiquitylase ataxin-3 interacts with LC3C/GABARAP and promotes autophagy. *Aging Cell* [Internet]. 2020 [citado 11 dic 2020]; 19(1). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974715/pdf/ACEL-19-e13051.pdf>.

**H**ou X, Gong X, Zhang L, Li T, Yuan H, Xie Y, et al. Identification of a potential exosomal biomarker in spinocerebellar ataxia Type 3/ Machado-Joseph disease. *Epigenomics* [Internet]. 2019 [citado 11 dic 2020]; 11(9). Disponible en: [https://www.futuremedicine.com/doi/10.2217/epi-2019-0081?url\\_ver=Z39.88-2003&rfr\\_id=ori%3Arid%3Arid%3Arid](https://www.futuremedicine.com/doi/10.2217/epi-2019-0081?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Arid%3Arid)

[3Acrossref.org&rfr\\_dat=cr\\_pub++0pubmed](https://pubmed.ncbi.nlm.nih.gov/36000000/)  
&.

**Hsieh M, Hsieh BY, Ma C-Y, Li Y-T, Liu C-S, Lo C-M.** Protective roles of carbonic anhydrase 8 in Machado–Joseph Disease. *Journal of Neuroscience Research* [Internet]. 2019 [citado 11 dic 2020]; 97(10). Disponible en: <https://onlinelibrary.wiley.com/doi/epdf/10.1002/jnr.24474>.

**Krauss S, Evert BO.** The Role of MicroRNAs in Spinocerebellar Ataxia Type 3. *Journal of Molecular Biology* [Internet]. 2019 [citado 11 dic 2020]; 431(9). Disponible en: <https://www.sciencedirect.com/science/article/pii/S0022283619300282/pdf?md5=4ade7cd4c06fc9ba005a9cf940e95a55&pid=1-s2.0-S0022283619300282-main.pdf>.

**Li T, Martins S, Peng Y, Wang P, Hou X, Chen Z, et al.** Is the High Frequency of Machado-Joseph Disease in China Due to New Mutational Origins? *Frontiers in genetics* [Internet]. 2018 [citado 11 dic 2020]; 9. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391318/pdf/fgene-09-00740.pdf>.

**Marchal-Muñoz A, García-Aranda M, Marchal-Muñoz M, Marchal-Escalona C, M R.** Efecto de la rehabilitación física en pacientes con ataxia espino cerebelosa hereditaria. Una revisión sistemática. *Rehabilitación* [Internet]. 2020 [citado 11 dic 2020]; 54(3). Disponible en: [https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0048712020300116.pdf?locale=es\\_ES&searchIndex=](https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0048712020300116.pdf?locale=es_ES&searchIndex=).

**Martier R, Sogorb-Gonzalez M, Stricker-Shaver J, Hübener-Schmid J, Keskin S, Klima J, et al.** Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease. *Molecular Therapy - Methods & Clinical Development* [Internet]. 2019 [citado 11 dic 2020]; 15. Disponible en: <https://www.sciencedirect.com/science/article/pii/S2329050119301160/pdf?md5=0f3dcd600a8196268b6ff824ad99b813&pid=1-s2.0-S2329050119301160-main.pdf>.

**Matos CA, de Almeida LP, Nóbrega C.** Machado–Joseph disease/ spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. *Journal of Neurochemistry* [Internet]. 2019 [citado 11 dic 2020]; 148(1). Disponible en: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/jnc.14541>.

**Mendes Á, Paneque M, Clarke A, Sequeiros J.** Choosing not to know: accounts of non-engagement with pre-symptomatic testing for Machado-Joseph disease. *European Journal of Human Genetics* [Internet]. 2019 [citado 11 dic 2020]; 27(3). Disponible en: <https://www.nature.com/articles/s41431-018-0308-y.pdf>.

**Mitchell N, LaTouche GA, Nelson B, Figueroa KP, Walker RH, Sobering AK.** Childhood-Onset Spinocerebellar Ataxia 3: Tongue Dystonia as an Early Manifestation. *Tremor Other Hyperkinet Mov (N Y)* [Internet]. 2019 [citado 11 dic 2020]; 9. Disponible en: <https://>

---

[www.ncbi.nlm.nih.gov/pmc/articles/PMC6744815/pdf/tre-09-704.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744815/pdf/tre-09-704.pdf).

**M**onte TL, Reckziegel EdR, Augustin MC, Locks-Coelho LD, Santos ASP, Furtado GV, et al. The progression rate of spinocerebellar ataxia type 2 changes with stage of disease. *Orphanet Journal of Rare Diseases* [Internet]. 2018 [citado 11 dic 2020]; 13(1). Disponible en <https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-017-0725-y.pdf>.

**M**oura Rezende Filho Flávio, Cardoso Vale Thiago, Pedrosa José Luiz, Braga-Neto Pedro, G BO. Facial grimacing and clinical correlates in spinocerebellar ataxia type 3 *Journal of the Neurological Sciences* [Internet]. 2019 [citado 11 dic 2020]; 397. Disponible en: [https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0022510X19300012.pdf?locale=es\\_ES&searchIndex=](https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0022510X19300012.pdf?locale=es_ES&searchIndex=).

**N**omura T, Iwata I, Harada T, Yabe I. Cerebellar Rotation Abnormalities Observed in Machado-Joseph Disease. *Internal Medicine* [Internet]. 2021 [citado 11 dic 2020]. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/32788542/>.

**O**liveira Miranda C, Marcelo A, Silva TP, Barata J, Vasconcelos-Ferreira A, Pereira D, et al. Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease. *Molecular Therapy* [Internet]. 2018 2018/09/05/ [citado 11 dic 2020]; 26(9). Disponible en: <https://www.sciencedirect.com/science/article/pii/S1525001618303149/pdff?md5=f1b304f1f8eb9ae54db85b83250e81b4&pid=1-s2.0-S1525001618303149-main.pdf>.

**O**liveira Scott Stephanie Suzanne de, Pedrosa José Luiz, Povoas Barsottini Orlando Graziani, Cavalcante França-Junior Marcondes, Pedro B-N. Natural history and epidemiology of the spinocerebellar ataxias: Insights from the first description to nowadays. *Journal of the Neurological Sciences* [Internet]. 2020 [citado 11 dic 2020]; 417. Disponible en: [https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0022510X20304196.pdf?locale=es\\_ES&searchIndex=](https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0022510X20304196.pdf?locale=es_ES&searchIndex=).

**P**aybast S, Koosha M, Motamedi D, Habibi A. Spinocerebellar Atrophy Type-3 with Chiari Malformation in a Young Man: A Case Report. *Advanced journal of emergency medicine* [Internet]. 2020 [citado 11 dic 2020]; 4(2). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163268/pdf/AJEM-4-e30.pdf>.

**P**elayo J, Rau N, Lo K, Azmaiparashvili Z. Familial spontaneous pneumothorax and Machado-Joseph disease. *Oxf Med Case Reports* [Internet]. 2020 [citado 11 dic 2020]; 2020(9). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507872/pdf/omaa078.pdf>

**P**iccinin CC, Rezende TJR, de Paiva JLR, Moysés PC, Martinez ARM, Cendes F, et al. A 5-Year Longitudinal Clinical and Magnetic Resonance Imaging Study in Spinocerebellar Ataxia Type 3. *Movement Disorders* [Internet]. 2020 [citado 11 dic 2020]; 35(9). Disponible en <https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.28113>.

**P**ohl F, Teixeira-Castro A, Costa MD, Lindsay V, Fiúza-Fernandes J, Goua M, et al. GST-4-Dependent Suppression of Neurodegeneration in *C. elegans* Models of Parkinson's and Machado-Joseph Disease by Rapeseed Pomace Extract Supplementation. *Front Neurosci* [Internet]. 2019 [citado 11 dic 2020]; 13. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811615/pdf/fnins-13-01091.pdf>.

**P**ulido-Valdeolivas I, Gómez-Andrés D, Sanz-Gallego I, Rausell E, Arpa J. Patterns of motor signs in spinocerebellar ataxia type 3 at the start of follow-up in a reference unit. *Cerebellum & Ataxias* [Internet]. 2016 [citado 11 dic 2020]; 3(1). Disponible en: <https://cerebellumandataxias.biomedcentral.com/track/pdf/10.1186/s40673-016-0042-6.pdf>

**S**ena LS, dos Santos Pinheiro J, Saraiva-Pereira ML, Jardim LB. Selective forces acting on spinocerebellar ataxia type 3/ Machado–Joseph disease recurrency: A systematic review and meta-analysis. *Clinical Genetics* [Internet]. 2020 [citado 11 dic 2020]; n/a(n/a). Disponible en: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/cge.13888>.

**S**hindo K, Sato T, Murata H, Ichinose Y, Hata T, Takiyama Y. Spinocerebellar ataxia type 31 associated with REM sleep behavior disorder: a case report. *BMC Neurology* [Internet]. 2019 [citado 11 dic 2020]; 19(1). Disponible en: <https://bmcneurol.biomedcentral.com/track/pdf/10.1186/s12883-019-1238-1.pdf>.

**S**hirai S, Yabe I, Naganuma R, Sato C, Takahashi I, Matsushima M, et al. Tremor during orthostatism as the initial symptom of Machado-Joseph disease. *Clinical neurology and neurosurgery* [Internet]. 2018 [citado 11 dic 2020]; 173. Disponible en: [https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0303846718303202.pdf?locale=es\\_ES&searchIndex=](https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0303846718303202.pdf?locale=es_ES&searchIndex=).

**S**ullivan R, Yau WY, O'Connor E, Houlden H. Spinocerebellar ataxia: an update. *Journal of Neurology* [Internet]. 2019 [citado 11 dic 2020]; 266(2). Disponible en: <https://link.springer.com/content/pdf/10.1007/s00415-018-9076-4.pdf>

**T**iburtino Meira Alex, Oleschko Arruda Walter, Eiji Ono Sergio, Leite Franklin Gustavo, Carvalho Neto Arnolfo de, Raskin Salmo, et al. Analysis of diffusion tensor parameters in spinocerebellar ataxia type 3 and type 10 patients. *Parkinsonism and Related Disorders* [Internet]. 2020 [citado 11 dic 2020]; 78. Disponible en: [https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S1353802020306374.pdf?locale=es\\_ES&searchIndex=](https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S1353802020306374.pdf?locale=es_ES&searchIndex=).

**W**ei L, Zhang J, Chen D, Feng L, Wu C, Wang R, et al. Generation of an integration-free induced pluripotent stem cell (iPSC) line (ZZUNEUi002-A) from a patient with spinocerebellar ataxia type 3. *Stem Cell Research* [Internet]. 2020 2020/08/01/ [citado 11 dic 2020]; 47. Disponible en: <https://www.sciencedirect.com/science/article/pii/S1873506120301999/pdf?md5=385266231cfea0376c90d0ff9b995c23&pid=1-s2.0-S1873506120301999-main.pdf>.



---

**X**u HL, Su QN, Shang XJ. The influence of initial symptoms on phenotypes in spinocerebellar ataxia type 3. *Molecular genetics & genomic medicine* [Internet]. 2019 [citado 11 dic 2020]; 7(7). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625145/pdf/MGG3-7-e00719.pdf>.

**Y**ang ZH, Shi CH, Zhou LN, Li YS, Yang J, Liu YT, et al. Metabolic Profiling Reveals Biochemical Pathways and Potential Biomarkers of Spinocerebellar Ataxia 3. *Front Mol Neurosci* [Internet]. 2019 [citado 11 dic 2020]; 12. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611058/pdf/fnmol-12-00159.pdf>.

**Z**eng C, Zhao C, Ge F, Li Y, Cao J, Ying M, et al. Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets. *Front Pharmacol* [Internet]. 2020 [citado 11 dic 2020]; 11. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479174/pdf/fphar-11-01311.pdf>.

**Elaborado por:**

**Grupo Gestión de Información en  
Salud  
Centro Provincial Información de  
Ciencias Médicas Camagüey,  
2020.**

**[http://www.cmw.sld.cu/  
pagina/2020/10/13/boletin-bibliografico](http://www.cmw.sld.cu/pagina/2020/10/13/boletin-bibliografico)**

**DESCRIPTORES**

**DeCS**

ENFERMEDAD DE MACHADO-  
JOSEPH

**MeSH**

MACHADO-JOSEPH DISEASE

**Límites:**

Fecha de publicación: 2017-2020

Idiomas: Español/Inglés/portugués

Publicaciones académicas  
(arbitradas)

Texto completo: PDF/Html

**BASES DE DATOS Y SITIOS CONSULTADOS**

